Supercharge Your TFSA With These 3 Growth Stocks

Here’s why investors should consider holding quality growth stocks such as Docebo and Datadog in a TFSA to benefit from outsized gains.

| More on:
TFSA (Tax free savings account) acronym on wooden cubes on the background of stacks of coins

Source: Getty Images

The primary benefit of holding quality growth stocks in a Tax-Free Savings Account (TFSA) is to generate tax-sheltered market-beating returns. Any returns generated in this registered account from qualified investments are exempt from taxes.

Imagine investing $1,000 in Shopify soon after its IPO (initial public offering) and holding it in a TFSA. Today, the investment would be worth more than $36,000, all of which is tax-free.

Here, I have identified three other quality growth stocks that can supercharge your TFSA portfolio in the upcoming decade.

CrowdStrike stock

Down 32% from all-time highs, CrowdStrike (NASDAQ:CRWD) is among the largest cyber-security companies in the world. Valued at US$74 billion by market cap, CrowdStrike has already returned 421% to shareholders since its IPO in 2019.

CrowdStrike has increased its sales from US$481 million in fiscal 2020 (ended in January) to over US$3 billion in fiscal 2024. In the last 12 months, its revenue has risen by 33% year over year to US$3.5 billion.

Unlike other unprofitable growth stocks, CrowdStrike has reported free cash flow of US$1.2 billion in the last four quarters, indicating a margin of 33.4%. Moreover, its free cash flow has risen from less than US$20 million in fiscal 2020, which showcases the company’s high operating leverage.

CrowdStrike ended fiscal Q2 of 2025 with annual recurring revenue, or ARR, of US$3.9 billion, an increase of 32% year over year. Its operating margin improved by two percentage points to 24%, while free cash flow rose by 44% to US$272 million.

The company has forecast its total addressable market at US$100 billion, which means its growth story is far from over.

Docebo stock

A Canadian company part of the e-learning segment, Docebo (TSX:DCBO) should be part of your TFSA portfolio in 2024. Valued at $1.9 billion by market cap, Docebo ended Q2 with 3,898 customers and US$206 million in annual recurring revenue.

Its subscription sales account for 94% of the top line, which should enable Docebo to report stable cash flows across market cycles. Moreover, 81% of the ARR added in 2023 was represented by customers who chose multi-year contracts.

Docebo’s average annual contract value rose from US$12,000 in 2014 to US$52,000 in Q2 2024. Further, its net dollar retention rate stood at 104%, which suggests that existing customers increased spending on the platform by 4% in the last year.

Like CrowdStrike, Docebo is also profitable, reporting free cash flow of US$27 million in the last 12 months, up from US$15 million in 2023.

Datadog stock

The final growth stock on the list is Datadog (NASDAQ:DDOG). Valued at US$43 billion by market cap, Datadog provides an enterprise-facing monitoring and analytics platform for developers.

In the last five years, the company has grown its revenue at an exceptional compound annual growth rate of 55%. This rapid revenue growth allowed Datadog to report free cash flow of US$715 million in the last 12 months, up from US$632 million in 2023 and US$383 million in 2022. In the June quarter, it reported free cash flow of US$144 million, indicating a margin of 22%.

In Q2 2024, Datadog increased sales by 27% to US$645 million. It ended the quarter with 28,700 customers, up from 26,100 in the year-ago period. Further, 3,390 customers generated annual recurring revenue of US$100,000 in Q2, up from 2,990 last year.

Down 35% from all-time highs, Datadog remains positioned to deliver outsized returns to shareholders in 2024 and beyond.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Aditya Raghunath has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Shopify. The Motley Fool recommends CrowdStrike, Datadog, and Docebo. The Motley Fool has a disclosure policy.

More on Tech Stocks

Man data analyze
Tech Stocks

3 Reasons Celestica Stock Is a Screaming Buy Now

These three reasons make Celestica stock a screaming buy for long-term investors.

Read more »

profit rises over time
Dividend Stocks

These 2 Dow Stocks Are Set to Soar in 2025 and Beyond

Two Dow Jones stocks are screaming buys but Canadians must hold them in an RRSP or RRIF to avoid paying…

Read more »

telehealth stocks
Tech Stocks

Well Health Stock: Buy, Sell, or Hold?

Another record-breaking quarter and strong demand sets the stage for continued momentum for Well Health stock.

Read more »

3 colorful arrows racing straight up on a black background.
Dividend Stocks

TSX Stocks Soaring Higher With No Signs of Slowing

Three TSX stocks continue to beat the market and could soar higher in an improving investment landscape.

Read more »

profit rises over time
Tech Stocks

2 Non-AI Tech Stocks to Buy in November for Better Returns

Not all AI stocks are riding the hype train, and for many investors, well-understood and predictable growth stocks might be…

Read more »

worry concern
Tech Stocks

In a Few Years, You’ll Probably Regret Not Owning BlackBerry Stock

Here’s why I believe BlackBerry could be one of the most overlooked Canadian tech stocks right now.

Read more »

A worker uses a double monitor computer screen in an office.
Tech Stocks

Is Constellation Software Stock a Buy for its 0.25% Dividend Yield?

Here's what investors may want to consider when it comes to Dollarama (TSX:DOL) and its relatively low dividend yield.

Read more »

Nurse talks with a teenager about medication
Tech Stocks

Shares of WELL Health Just Zoomed. Is It a Buy?

Given its improving financials and healthy growth prospects, WELL Health could deliver superior returns over the next three years.

Read more »